News
In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...
Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.
Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...
In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...
Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results